Read by QxMD icon Read

pet head neck radiotherapy

Julie Schatteman, Dirk Van Gestel, Dieter Berwouts, Werner De Gersem, Geert De Kerf, Wilfried De Neve, Bie De Ost, Ana Maria Luiza Olteanu, Sylvie Rottey, Tom Vercauteren, Ingeborg Goethals, Fréderic Duprez
PURPOSE: To evaluate feasibility, disease control, survival, and toxicity after adaptive18 F-fluorodeoxyglucose (FDG) positron emisson tomography (PET) guided radiotherapy in patients with recurrent and second primary head and neck squamous cell carcinoma. METHODS: A prospective trial investigated the feasibility of adaptive intensity modulated radiotherapy (IMRT) ± concomitant cetuximab in 10 patients. The primary endpoint was achieving a 2-year survival free of grade >3 toxicity in ≥30% of patients...
March 19, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Thomas J W Klein Nulent, Matthijs H Valstar, Bart de Keizer, Stefan M Willems, Laura A Smit, Abrahim Al-Mamgani, Ludwig E Smeele, Robert J J van Es, Remco de Bree, Wouter V Vogel
OBJECTIVES: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is used for detection and (re)staging of prostate cancer. However, healthy salivary, seromucous, and lacrimal glands also have high PSMA-ligand uptake. This study aimed to describe physiologic PSMA-ligand uptake distribution characteristics in the head and neck to aid in PSMA PET/CT interpretation and to identify possible new clinical applications for PSMA-ligand imaging. STUDY DESIGN: Thirty consecutive patients who underwent PSMA PET/CT for prostate cancer were evaluated...
January 31, 2018: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Nils Helsen, Tim Van den Wyngaert, Laurens Carp, Sigrid Stroobants
PURPOSE: 18-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) is increasingly used to evaluate treatment response in head and neck squamous cell carcinoma (HNSCC). This analysis assessed the diagnostic value of FDG-PET/CT in detecting nodal disease within 6 months after treatment, considering patient and disease characteristics. METHODS: A systematic review was performed using the MEDLINE and Web of Knowledge databases...
February 24, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Masao Takenobu, Sueyoshi Moritani, Kana Yoshioka, Tsuyoshi Morisaki, Hiroya Kitano
Thyroid metastasis from head and neck squamous cell carcinoma (SCC) is a very rare form of rarely observed metastatic thyroid tumor. We herein report a case of thyroid metastasis from oropharyngeal SCC (OSCC). The patient was a 68-year-old male diagnosed with p16-positive tonsillar OSCC on the right side with multiple lymph node metastases and a thyroid mass, which was determined as metastatic p16-positive OSCC by immunohistochemistry of specimens collected by fine-needle aspiration cytology (FNAC). He received one cycle of induction chemotherapy followed by concurrent chemoradiotherapy...
February 15, 2018: Endocrine Journal
Remco de Bree, Asaf Senft, Andrés Coca-Pelaz, Luiz Kowalski, Fernando Lopez, William Mendenhall, Miquel Quer, Alessandra Rinaldo, Ashok R Shaha, Primož Strojan, Robert P Takes, Carl E Silver, C René Leemans, Alfio Ferlito
As head and neck squamous cell carcinoma (HNSCC) patients with distant metastases (DM) were generally treated only palliatively, the value of screening for DM was usually limited to attempts to avoid extensive locoregional treatment when DM were present pretreatment. Recently, the concept of treating oligometastases, e.g., by metastatectomy or stereotactic body radiotherapy, has been reintroduced for HNSCC and may cause a change in the treatment paradigm. Although whole body 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) combined with computed tomography (CT; WB-FDG-PET/CT) is still the mainstay diagnostic technique, there is a growing body of evidence supporting implementation of whole body magnetic resonance imaging (WB-MRI) as an important diagnostic technique for screening for DM...
February 2, 2018: Advances in Therapy
Jwala Philip, Ekin Ermiş, Finbar Slevin, Sriram Vaidyanathan, Mehmet Sen, Andrew F Scarsbrook, Robin J D Prestwich
FDG PET-CT is an established tool for response assessment following definitive concurrent chemoradiotherapy for head and neck squamous cell carcinoma with a high negative predictive value guiding treatment decisions. Little data is available regarding the accuracy of FDG PET-CT for response assessment following definitive radiotherapy without chemotherapy. We retrospectively analysed the accuracy of FDG PET-CT for response assessment following radiotherapy alone without planned neck dissection in 45 patients...
January 11, 2018: Clinical Otolaryngology
Rui-Yun Chen, Ying-Chun Lin, Wei-Chih Shen, Te-Chun Hsieh, Kuo-Yang Yen, Shang-Wen Chen, Chia-Hung Kao
To know tumor PD-L1 expression through IHC or the FDG-PET related radiomics, we investigated the association between programmed cell death protein 1 ligand (PD-L1) expression and immunohistochemical (IHC) biomarkers or textural features of 18F-fluoro-2-deoxdeoxyglucose positron emission tomography (18 F-FDG PET) in 53 oropharyngeal or hypopharyngeal cancer patients who were ready to undergo radiotherapy-based treatment. Differences in textural features or biomarkers between tumors with and without PD-L1 expression were tested using a Mann-Whitney U test...
January 8, 2018: Scientific Reports
Jingping Qiu, Lingrong Tang, Yang Han, Chun Wang, Tianxiang Gu, Guang Li
RATIONALE: Fibromyxosarcoma is common in head and neck, vessel, omentum, and reproductive system, with low-grade malignant behavior. However, primary atrial fibromyxosarcoma with highly malignant behavior is extremely rare. PATIENT CONCERNS: A 34-year-old female presented with oppression in the chest, short breath, and onset of headache as initial symptoms. The preoperative echocardiogram showed a medium-size echogenic mass close to the posterior leaflet of the mitral valve in the left atrium...
December 2017: Medicine (Baltimore)
Tilmann Bochtler, Harald Löffler, Alwin Krämer
In cancer of unknown primary (CUP), metastases are clinically and histologically confirmed, but the primary tumor site remains elusive after extensive work-up. CUPs make up for 2-3% of all epithelial malignancies. The two prevailing histologies are adenocarcinomas and undifferentiated carcinomas, whereas squamous cell carcinomas, neuroendocrine carcinomas and rare histologies account for the remaining 10%. The diagnostic work-up in CUP relies strongly on a detailed immunohistological (IHC) analysis in order to characterize the tumor type, nowadays aided by molecular techniques...
November 26, 2017: Seminars in Diagnostic Pathology
Alexander Dellweg, Thomas Mantei
OBJECTIVES: Our aim was to investigate the metastasis behavior and its prognostic Factor for Survival, with our clinical data. MATERIALS AND METHODS: This retrospective study included 29 Caucasians, with a squamous cell carcinoma of the skin in the head and neck region, at our tertiary clinic between 2004 and 2016. All Patients received a Tumorresection and Neckdissection. We used either Ultrasound or Computer-Tomography (conventional or PET-CT) for our preoperative Staging and the Follow-up...
February 2018: Laryngo- Rhino- Otologie
Eleonora Farina, Martina Ferioli, Paolo Castellucci, Arianna Farina, Giuseppe Zanirato Rambaldi, Savino Cilla, Silvia Cammelli, Stefano Fanti, Alessio G Morganti
BACKGROUND/AIM: A review of the literature is proposed as a contribution to current knowledge on technical, physical, and clinical issues about PET-guided planning and re-planning radiotherapy (RT) in head and neck cancer. MATERIALS AND METHODS: PubMed and Scopus electronic databases were searched for articles including clinical trials. Search terms were "gross tumor volume (GTV) delineation", "head and neck cancer", "radiotherapy", "adaptive radiotherapy" in combination with "PET"...
December 2017: Anticancer Research
Pierre Decazes, Sébastien Thureau, Bernard Dubray, Pierre Vera
INTRODUCTION: Radiotherapy is a major treatment modality for many cancers. Tumor response after radiotherapy determines the subsequent steps of the patient's management (surveillance, adjuvant or salvage treatment and palliative care). Tumor response assessed during radiotherapy offers a promising opportunity to adapt the treatment plan to reduced / increased target volume, to specifically target sub-volumes with relevant biological characteristics (metabolism, hypoxia, proliferation ...
November 28, 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
Vincent Grégoire, Daniela Thorwarth, John Aldo Lee
With the routine use of intensity modulated radiation therapy for the treatment of head-and-neck squamous cell carcinoma allowing highly conformed dose distribution, there is an increasing need for refining both the selection and the delineation of gross tumor volumes (GTV). In this framework, molecular imaging with positron emission tomography and magnetic resonance imaging offers the opportunity to improve diagnostic accuracy and to integrate tumor biology mainly related to the assessment of tumor cell density, tumor hypoxia, and tumor proliferation into the treatment planning equation...
January 2018: Seminars in Radiation Oncology
Antti Silvoniemi, Sami Suilamo, Timo Laitinen, Sarita Forsback, Eliisa Löyttyniemi, Samuli Vaittinen, Virva Saunavaara, Olof Solin, Tove J Grönroos, Heikki Minn
PURPOSE: Hypoxia contributes to radiotherapy resistance and more aggressive behaviour of several types of cancer. This study was designed to evaluate the repeatability of intratumour uptake of the hypoxia tracer [(18)F]EF5 in paired PET/CT scans. METHODS: Ten patients with newly diagnosed head and neck cancer (HNC) received three static PET/CT scans before chemoradiotherapy: two with [(18)F]EF5 a median of 7 days apart and one with [(18)F]FDG. Metabolically active primary tumour volumes were defined in [(18)F]FDG images and transferred to co-registered [(18)F]EF5 images for repeatability analysis...
October 26, 2017: European Journal of Nuclear Medicine and Molecular Imaging
Michał Płachta, Witold Cholewiński, Ewa Burchardt, Paulina Cegła, Bartosz Urbański, Żaneta Wareńczak-Florczak, Andrzej Roszak
OBJECTIVES: The aim of this study was to present strategy and early results of treatment of advanced cervical cancer patients with synchronous cancers observed in PET-CT imaging, treated at the Greater Poland Cancer Center. MATERIAL AND METHODS: The study included a group of 200 patients with diagnosed stage IIB-IIIB cervical cancer who received PET-CT for the purpose of radiotherapy treatment planning. RESULTS: Among our study group, four patients (2%) were found to have a synchronous cancer...
2017: Ginekologia Polska
T A Szyszko, G J R Cook
Combined 2-[ 18 F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET)/computed tomography (CT) has an established role in the staging of difficult cases of head and neck (HN) squamous cell carcinoma (SCC), looking for an unknown primary, assessing response post-chemotherapy at 3-6 months, and differentiating relapse from treatment effects in patients suspected to have tumour recurrence. The PET NECK trial, comparing PET/CT surveillance versus neck dissection in advanced head and neck cancer showed survival was similar among patients who underwent PET/CT-guided surveillance and those who underwent planned neck dissection, but surveillance was more cost-effective...
January 2018: Clinical Radiology
Lisanne V van Dijk, Walter Noordzij, Charlotte L Brouwer, Ronald Boellaard, Johannes G M Burgerhof, Johannes A Langendijk, Nanna M Sijtsema, Roel J H M Steenbakkers
BACKGROUND AND PURPOSE: Current prediction of radiation-induced xerostomia 12months after radiotherapy (Xer12m) is based on mean parotid gland dose and baseline xerostomia (Xerbaseline) scores. The hypothesis of this study was that prediction of Xer12m is improved with patient-specific characteristics extracted from (18)F-FDG PET images, quantified in PET image biomarkers (PET-IBMs). PATIENTS AND METHODS: Intensity and textural PET-IBMs of the parotid gland were collected from pre-treatment (18)F-FDG PET images of 161 head and neck cancer patients...
September 23, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Anders Elias Hansen, Frederikke Petrine Fliedner, Jonas Rosager Henriksen, Jesper Tranekjær Jørgensen, Andreas Ettrup Clemmensen, Betina Børresen, Dennis Ringkjøbing Elema, Andreas Kjær, Thomas Lars Andresen
Radiation therapy may affect several important parameters in the tumor microenvironment and thereby influence the accumulation of liposomes by the enhanced permeability and retention (EPR)-effect. Here we investigate the effect of single dose radiation therapy on liposome tumor accumulation by PET/CT imaging using radiolabeled liposomes. Head and neck cancer xenografts (FaDu) and syngenic colorectal (CT26) cancer models were investigated. Radiotherapy displayed opposite effects in the two models. FaDu tumors displayed increased mean accumulation of liposomes for radiation doses up to 10 Gy, whereas CT26 tumors displayed a tendency for decreased accumulation...
September 4, 2017: Nanomedicine: Nanotechnology, Biology, and Medicine
A F Smith, P S Hall, C T Hulme, J A Dunn, C C McConkey, J K Rahman, C McCabe, H Mehanna
BACKGROUND: A recent large United Kingdom (UK) clinical trial demonstrated that positron-emission tomography-computed tomography (PET-CT)-guided administration of neck dissection (ND) in patients with advanced head and neck cancer after primary chemo-radiotherapy treatment produces similar survival outcomes to planned ND (standard care) and is cost-effective over a short-term horizon. Further assessment of long-term outcomes is required to inform a robust adoption decision. Here we present results of a lifetime cost-effectiveness analysis of PET-CT-guided management from a UK secondary care perspective...
November 2017: European Journal of Cancer
Steffen Löck, Rosalind Perrin, Annekatrin Seidlitz, Anna Bandurska-Luque, Sebastian Zschaeck, Klaus Zöphel, Mechthild Krause, Jörg Steinbach, Jörg Kotzerke, Daniel Zips, Esther G C Troost, Michael Baumann
BACKGROUND: Hypoxia is a well recognised parameter of tumour resistance to radiotherapy, a number of anticancer drugs and potentially immunotherapy. In a previously published exploration cohort of 25 head and neck squamous cell carcinoma (HNSCC) patients on [(18)F]fluoromisonidazole positron emission tomography (FMISO-PET) we identified residual tumour hypoxia during radiochemotherapy, not before start of treatment, as the driving mechanism of hypoxia-mediated therapy resistance. Several quantitative FMISO-PET parameters were identified as potential prognostic biomarkers...
September 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"